Hans Schreiber to Immunotherapy
This is a "connection" page, showing publications Hans Schreiber has written about Immunotherapy.
Connection Strength
1.140
-
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med. 2010 Oct 25; 207(11):2469-77.
Score: 0.260
-
Tumor-specific immune responses. Semin Immunol. 2008 Oct; 20(5):265-6.
Score: 0.228
-
Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
Score: 0.224
-
Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
Score: 0.139
-
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
Score: 0.097
-
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am. 2006 Jun; 20(3):567-84.
Score: 0.048
-
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004 Feb; 5(2):141-9.
Score: 0.041
-
Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res. 2001 Mar; 7(3 Suppl):871s-875s.
Score: 0.033
-
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
Score: 0.030
-
Tumor antigens. Annu Rev Immunol. 1992; 10:617-44.
Score: 0.018
-
Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity. Cell Immunol. 1989 Mar; 119(1):101-13.
Score: 0.015
-
Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. J Immunol. 1990 Apr 01; 144(7):2840-6.
Score: 0.004
-
In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science. 1988 Oct 28; 242(4878):569-71.
Score: 0.004